Association between EZH2 expression, silencing of tumor suppressors and disease outcome in solid tumors

References

• Plass C, Pfister SM, Lindroth AM, Bogatyrova O, Claus R, Lichter P. Mutations in regulators of the epigenome and their connections to global chromatin patterns in cancer. Nat Rev Genet 2013; 14:765-80; PMID:24105274; http://dx.doi.org/10.1038/nrg3554
   PubMed Web of Science ®Google Scholar
• Shah MA, Denton EL, Arrowsmith CH, Lupien M, Schapira M. A global assessment of cancer genomic alterations in epigenetic mechanisms. Epigenetics Chromatin 2014; 7:29; PMID:25484917; http://dx.doi.org/10.1186/1756-8935-7-29
   PubMed Web of Science ®Google Scholar
• Simon JA, Kingston RE. Mechanisms of Polycomb gene silencing: knowns and unknowns. Nat Rev Mol Cell Biol 2009; 10:1-12; http://dx.doi.org/10.1038/nrn2589
   Web of Science ®Google Scholar
• Kleer CG, Cao Q, Varambally S, Shen R, Ota I, Tomlins SA, Ghosh D, Sewalt RGAB, Otte AP, Hayes DF, et al. EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Proc Natl Acad Sci U S A 2003; 100:11606-11; PMID:14500907; http://dx.doi.org/10.1073/pnas.1933744100
   PubMed Web of Science ®Google Scholar
• Varambally S, Dhanasekaran SM, Zhou M, Barrette TR, Kumar-Sinha C, Sanda MG, Ghosh D, Pienta KJ, Sewalt RGAB, Otte AP, et al. The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature 2002; 419:624-9;; PMID:12374981; http://dx.doi.org/10.1038/nature01075
   PubMed Web of Science ®Google Scholar
• Koh CM, Iwata T, Zheng Q, Bethel C, Yegnasubramanian S, De Marzo AM. Abstract 263: MYC enforces overexpression of EZH2 in early prostatic neoplasia via transcriptional and posttranscriptional mechanisms. Cancer Res 2011; 71:263-263;; http://dx.doi.org/10.1158/1538-7445.AM2011-263
   Web of Science ®Google Scholar
• Bracken AP, Pasini D, Capra M, Prosperini E, Colli E, Helin K. EZH2 is downstream of the pRB-E2F pathway, essential for proliferation and amplified in cancer. EMBO J 2003; 22:5323-35; PMID:14532106; http://dx.doi.org/10.1093/emboj/cdg542
   PubMed Web of Science ®Google Scholar
• Ren G, Baritaki S, Marathe H, Feng J, Park S, Beach S, Bazeley PS, Beshir AB, Fenteany G, Mehra R, et al. Polycomb protein EZH2 regulates tumor invasion via the transcriptional repression of the metastasis suppressor RKIP in breast and prostate cancer. Cancer Res 2012; 72:3091-104;; PMID:22505648; http://dx.doi.org/10.1158/0008-5472.CAN-11-3546
   PubMed Web of Science ®Google Scholar
• Beke L, Nuytten M, Van Eynde A, Beullens M, Bollen M. The gene encoding the prostatic tumor suppressor PSP94 is a target for repression by the Polycomb group protein EZH2. Oncogene 2007; 26:4590-5; PMID:17237810; http://dx.doi.org/10.1038/sj.onc.1210248
   PubMed Web of Science ®Google Scholar
• Taniguchi H, Jacinto F V, Villanueva A, Fernandez AF, Yamamoto H, Carmona FJ, Puertas S, Marquez VE, Shinomura Y, Imai K, et al. Silencing of Kruppel-like factor 2 by the histone methyltransferase EZH2 in human cancer. Oncogene 2012; 31:1988-94; PMID:21892211; http://dx.doi.org/10.1038/onc.2011.387
   PubMed Web of Science ®Google Scholar
• Fujii S, Ito K, Ito Y, Ochiai A. Enhancer of zeste homologue 2 (EZH2) down-regulates RUNX3 by increasing histone H3 methylation. J Biol Chem 2008; 283:17324-32;; PMID:18430739; http://dx.doi.org/10.1074/jbc.M800224200
   PubMed Web of Science ®Google Scholar
• Yu J, Cao Q, Wu L, Dallol A, Li J, Chen G, Grasso C, Cao X, Lonigro RJ, Varambally S, et al. The neuronal repellent SLIT2 is a target for repression by EZH2 in prostate cancer. Oncogene 2010; 29:5370-80; PMID:20622896; http://dx.doi.org/10.1038/onc.2010.269
   PubMed Web of Science ®Google Scholar
• Chen H, Tu SW, Hsieh JT. Down-regulation of human DAB2IP gene expression mediated by polycomb Ezh2 complex and histone deacetylase in prostate cancer. J Biol Chem 2005; 280:22437-44; PMID:15817459; http://dx.doi.org/10.1074/jbc.M501379200
   PubMed Web of Science ®Google Scholar
• Bracken AP, Kleine-Kohlbrecher D, Dietrich N, Pasini D, Gargiulo G, Beekman C, Theilgaard-Mönch K, Minucci S, Porse BT, Marine J-C, et al. The Polycomb group proteins bind throughout the INK4A-ARF locus and are disassociated in senescent cells. Genes Dev 2007; 21:525-30; PMID:17344414; http://dx.doi.org/10.1101/gad.415507
   PubMed Web of Science ®Google Scholar
• Seward S, Semaan A, Qazi AM, Gruzdyn OV, Chamala S, Bryant CC, Kumar S, Cameron D, Sethi S, Ali-Fehmi R, et al. EZH2 blockade by RNA interference inhibits growth of ovarian cancer by facilitating re-expression of p21waf1/cip1 and by inhibiting mutant p53. Cancer Lett 2013; 336:53-60; PMID:23603558; http://dx.doi.org/10.1016/j.canlet.2013.04.012
   PubMed Web of Science ®Google Scholar
• Batchu RB, Qazi AM, Gruzdyn OV, Semaan A, Seward SM, Chamala S, Dhulipala VB, Bouwman DL, Weaver DW, Gruber SA. EZH2-shRNA-mediated upregulation of p21waf1/cip1 and its transcriptional enhancers with concomitant downmodulation of mutant p53 in pancreatic ductal adenocarcinoma. Surgery 2013; 154:739-46; discussion 746–7; PMID:24074410; http://dx.doi.org/10.1016/j.surg.2013.06.041
   PubMed Web of Science ®Google Scholar
• Bai J, Chen J, Ma M, Cai M, Xu F, Wang G, Tao K, Shuai X. Inhibiting enhancer of zeste homolog 2 promotes cellular senescence in gastric cancer cells SGC-7901 by activation of p21 and p16. DNA Cell Biol 2014; 33:337-44; PMID:24588771; http://dx.doi.org/10.1089/dna.2014.2340
   PubMed Web of Science ®Google Scholar
• Xu K, Wu ZJ, Groner AC, He HH, Cai C, Lis RT, Wu X, Stack EC, Loda M, Liu T, et al. EZH2 oncogenic activity in castration-resistant prostate cancer cells is Polycomb-independent. Science 2012; 338:1465-9; PMID:23239736; http://dx.doi.org/10.1126/science.1227604
   PubMed Web of Science ®Google Scholar
• Lee ST, Li Z, Wu Z, Aau M, Guan P, Karuturi RKM, Liou YC, Yu Q. Context-Specific Regulation of NF-κB Target Gene Expression by EZH2 in Breast Cancers. Mol Cell 2011; 43:798-810; PMID:21884980; http://dx.doi.org/10.1016/j.molcel.2011.08.011
   PubMed Web of Science ®Google Scholar
• Holm K, Grabau D, Lövgren K, Aradottir S, Gruvberger-Saal S, Howlin J, Saal LH, Ethier SP, Bendahl P-O, Stål O, et al. Global H3K27 trimethylation and EZH2 abundance in breast tumor subtypes. Mol Oncol 2012; 6:494-506; PMID:22766277; http://dx.doi.org/10.1016/j.molonc.2012.06.002
   PubMed Web of Science ®Google Scholar
• Wei Y, Xia W, Zhang Z, Liu J, Wang H, Adsay N V, Albarracin C, Yu D, Abbruzzese JL, Mills GB, et al. Loss of trimethylation at lysine 27 of histone H3 is a predictor of poor outcome in breast, ovarian, and pancreatic cancers. Mol Carcinog 2008; 47:701-6; PMID:18176935; http://dx.doi.org/10.1002/mc.20413
   PubMed Web of Science ®Google Scholar
• Bae WK, Yoo KH, Lee JS, Kim Y, Chung I-J, Park MH, Yoon JH, Furth PA, Hennighausen L. The methyltransferase EZH2 is not required for mammary cancer development, although high EZH2 and low H3K27me3 correlate with poor prognosis of ER-positive breast cancers. Mol Carcinog 2015; 54:1172-80; PMID:25043748; http://dx.doi.org/10.1002/mc.22188
   PubMed Web of Science ®Google Scholar
• Wassef M, Rodilla V, Teissandier A, Zeitouni B, Gruel N, Sadacca B, Irondelle M, Charruel M, Ducos B, Michaud A, et al. Impaired PRC2 activity promotes transcriptional instability and favors breast tumorigenesis. Genes Dev 2015; 29:1-16; PMID:25561492; http://dx.doi.org/10.1101/gad.253682.114
   PubMed Web of Science ®Google Scholar
• Pfau R, Tzatsos A, Kampranis SC, Serebrennikova OB, Bear SE, Tsichlis PN. Members of a family of JmjC domain-containing oncoproteins immortalize embryonic fibroblasts via a JmjC domain-dependent process. Proc Natl Acad Sci U S A 2008; 105:1907-12; PMID:18250326; http://dx.doi.org/10.1073/pnas.0711865105
   PubMed Web of Science ®Google Scholar
• Tzatsos A, Pfau R, Kampranis SC, Tsichlis PN. Ndy1/KDM2B immortalizes mouse embryonic fibroblasts by repressing the Ink4a/Arf locus. Proc Natl Acad Sci U S A 2009; 106:2641-6; PMID:19202064; http://dx.doi.org/10.1073/pnas.0813139106
   PubMed Web of Science ®Google Scholar
• Laitinen S, Martikainen PM, Tolonen T, Isola J, Tammela TLJ, Visakorpi T. EZH2, Ki-67 and MCM7 are prognostic markers in prostatectomy treated patients. Int J Cancer 2008; 122:595-602; PMID:17943722; http://dx.doi.org/10.1002/ijc.23145
   PubMed Web of Science ®Google Scholar
• Tolonen TT, Tammela TLJ, Kujala PM, Tuominen VJ, Isola JJ, Visakorpi T. Histopathological variables and biomarkers enhancer of zeste homologue 2, Ki-67 and minichromosome maintenance protein 7 as prognosticators in primarily endocrine-treated prostate cancer. BJU Int 2011; 108:1430-8; PMID:21592298; http://dx.doi.org/10.1111/j.1464-410X.2011.10253.x
   PubMed Web of Science ®Google Scholar
• Venet D, Dumont JE, Detours V. Most Random Gene Expression Signatures Are Significantly Associated with Breast Cancer Outcome. PLoS Comput Biol 2011; 7:e1002240; PMID:22028643; http://dx.doi.org/10.1371/journal.pcbi.1002240
   PubMed Web of Science ®Google Scholar
• Bachmann IM. EZH2 Expression Is Associated With High Proliferation Rate and Aggressive Tumor Subgroups in Cutaneous Melanoma and Cancers of the Endometrium, Prostate, and Breast. J Clin Oncol 2005; 24:268-73; PMID:16330673; http://dx.doi.org/10.1200/JCO.2005.01.5180
   PubMed Web of Science ®Google Scholar
• Nagalla S, Chou JW, Willingham MC, Ruiz J, Vaughn JP, Dubey P, Lash TL, Hamilton-Dutoit SJ, Bergh J, Sotiriou C, et al. Interactions between immunity, proliferation and molecular subtype in breast cancer prognosis. Genome Biol 2013; 14:R34; PMID:23618380; http://dx.doi.org/10.1186/gb-2013-14-4-r34
   PubMed Web of Science ®Google Scholar
• Ernst T, Chase AJ, Score J, Hidalgo-Curtis CE, Bryant C, Jones A V, Waghorn K, Zoi K, Ross FM, Reiter A, et al. Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders. Nat Genet 2010; 42:722-6; PMID:20601953; http://dx.doi.org/10.1038/ng.621
   PubMed Web of Science ®Google Scholar
• Simon C, Chagraoui J, Krosl J, Gendron P, Wilhelm B, Lemieux S, Boucher G, Chagnon P, Drouin S, Lambert R, et al. A key role for EZH2 and associated genes in mouse and human adult T-cell acute leukemia. Genes Dev 2012; 26:651-6; PMID:22431509; http://dx.doi.org/10.1101/gad.186411.111
   PubMed Web of Science ®Google Scholar
• Ntziachristos P, Tsirigos A, Van Vlierberghe P, Nedjic J, Trimarchi T, Flaherty MS, Ferres-Marco D, da Ros V, Tang Z, Siegle J, et al. Genetic inactivation of the polycomb repressive complex 2 in T cell acute lymphoblastic leukemia. Nat Med 2012; 18:298-303; PMID:22237151; http://dx.doi.org/10.1038/nm.2651
   PubMed Web of Science ®Google Scholar
• Score J, Hidalgo-Curtis C, Jones AV, Winkelmann N, Skinner A, Ward D, Zoi K, Ernst T, Stegelmann F, Döhner K, et al. Inactivation of polycomb repressive complex 2 components in myeloproliferative and myelodysplastic/myeloproliferative neoplasms. Blood 2012; 119:1208-13; PMID:22053108; http://dx.doi.org/10.1182/blood-2011-07-367243
   PubMed Web of Science ®Google Scholar
• Lee W, Teckie S, Wiesner T, Ran L, Prieto Granada CN, Lin M, Zhu S, Cao Z, Liang Y, Sboner A, et al. PRC2 is recurrently inactivated through EED or SUZ12 loss in malignant peripheral nerve sheath tumors. Nat Genet 2014; 46:1227-32; PMID:25240281; http://dx.doi.org/10.1038/ng.3095
   PubMed Web of Science ®Google Scholar
• De Raedt T, Beert E, Pasmant E, Luscan A, Brems H, Ortonne N, Helin K, Hornick JL, Mautner V, Kehrer-Sawatzki H, et al. PRC2 loss amplifies Ras-driven transcription and confers sensitivity to BRD4-based therapies. Nature 2014; 514:247-51; Available from: http://www.nature.com/doifinder/10.1038/nature13561; PMID:25119042
   PubMed Web of Science ®Google Scholar
• Zhang M, Wang Y, Jones S, Sausen M, McMahon K, Sharma R, Wang Q, Belzberg AJ, Chaichana K, Gallia GL, et al. Somatic mutations of SUZ12 in malignant peripheral nerve sheath tumors. Nat Genet 2014; 46:1170-2; PMID:25305755; http://dx.doi.org/10.1038/ng.3116
   PubMed Web of Science ®Google Scholar
• Cleven AH, Sannaa GA, Briaire-de Bruijn I, Ingram DR, van de Rijn M, Rubin BP, de Vries MW, Watson KL, Torres KE, Wang W, et al. Loss of H3K27 tri-methylation is a diagnostic marker for malignant peripheral nerve sheath tumors and an indicator for an inferior survival. Mod Pathol 2016; 29:582-90; http://dx.doi.org/10.1038/modpathol.2016.45
   Web of Science ®Google Scholar
• Wu G, Broniscer A, McEachron TA, Lu C, Paugh BS, Becksfort J, Qu C, Ding L, Huether R, Parker M, et al. Somatic histone H3 alterations in pediatric diffuse intrinsic pontine gliomas and non-brainstem glioblastomas. Nat Genet 2012; 44:251-3; PMID:22286216; http://dx.doi.org/10.1038/ng.1102
   PubMed Web of Science ®Google Scholar
• Lewis PW, Müller MM, Koletsky MS, Cordero F, Lin S, Banaszynski LA, Garcia BA, Muir TW, Becher OJ, Allis CD. Inhibition of PRC2 activity by a gain-of-function H3 mutation found in pediatric glioblastoma. Science 2013; 340:857-61; PMID:23539183; http://dx.doi.org/10.1126/science.1232245
   PubMed Web of Science ®Google Scholar
• Chan K-M, Fang D, Gan H, Hashizume R, Yu C, Schroeder M, Gupta N, Mueller S, James CD, Jenkins R, et al. The histone H3.3K27M mutation in pediatric glioma reprograms H3K27 methylation and gene expression. Genes Dev 2013; 27:985-90; PMID:23603901; http://dx.doi.org/10.1101/gad.217778.113
   PubMed Web of Science ®Google Scholar
• Mallen-St. Clair J, Soydaner-Azeloglu R, Lee KE, Taylor L, Livanos A, Pylayeva-Gupta Y, Miller G, Margueron R, Reinberg D, Bar-Sagi D. EZH2 couples pancreatic regeneration to neoplastic progression. Genes Dev 2012; 26:439-44; PMID:22391448; http://dx.doi.org/10.1101/gad.181800.111
   PubMed Web of Science ®Google Scholar
• de Vries NA, Hulsman D, Akhtar W, de Jong J, Miles DC, Blom M, van Tellingen O, Jonkers J, van Lohuizen M. Prolonged Ezh2 Depletion in Glioblastoma Causes a Robust Switch in Cell Fate Resulting in Tumor Progression. Cell Rep 2015; 10:383-97; http://dx.doi.org/10.1016/j.celrep.2014.12.028
   Web of Science ®Google Scholar
• Serresi M, Gargiulo G, Proost N, Siteur B, Cesaroni M, Koppens M, Xie H, Sutherland KD, Hulsman D, Citterio E, et al. Polycomb Repressive Complex 2 Is a Barrier to KRAS-Driven Inflammation and Epithelial-Mesenchymal Transition in Non-Small-Cell Lung Cancer. Cancer Cell 2016; 29:17-31; PMID:26766588; http://dx.doi.org/10.1016/j.ccell.2015.12.006
   PubMed Web of Science ®Google Scholar
• Ezhkova E, Pasolli HA, Parker JS, Stokes N, Su I, Hannon G, Tarakhovsky A, Fuchs E. Ezh2 Orchestrates Gene Expression for the Stepwise Differentiation of Tissue-Specific Stem Cells. Cell 2009; 136:1122-35; PMID:19303854; http://dx.doi.org/10.1016/j.cell.2008.12.043
   PubMed Web of Science ®Google Scholar
• Timp W, Feinberg AP. Cancer as a dysregulated epigenome allowing cellular growth advantage at the expense of the host. Nat Rev Cancer 2013; 13:497-510; PMID:23760024; http://dx.doi.org/10.1038/nrc3486
   PubMed Web of Science ®Google Scholar
• Rathert P, Roth M, Neumann T, Muerdter F, Roe J-S, Muhar M, Deswal S, Cerny-Reiterer S, Peter B, Jude J, et al. Transcriptional plasticity promotes primary and acquired resistance to BET inhibition. Nature 2015 [cited 2016 Jan 28]; 525:543-7; PMID:26367798; http://dx.doi.org/10.1038/nature14898
   PubMed Web of Science ®Google Scholar
• Curtis C, Shah SP, Chin S-F, Turashvili G, Rueda OM, Dunning MJ, Speed D, Lynch AG, Samarajiwa S, Yuan Y, et al. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature 2012; 486:346-52; Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artidD3440846&toolDpmcentrez&rendertypeDabstract; PMID:22522925
   PubMed Web of Science ®Google Scholar
• Taylor BS, Schultz N, Hieronymus H, Gopalan A, Xiao Y, Carver BS, Arora VK, Kaushik P, Cerami E, Reva B, et al. Integrative Genomic Profiling of Human Prostate Cancer. Cancer Cell 2010; PMID:20579941; 18:11-22; http://dx.doi.org/10.1016/j.ccr.2010.05.026
   PubMed Web of Science ®Google Scholar